Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Richard Auchus

Endocrinology, Diabetes & Metabolism Ann Arbor, MI Medical Doctor

NPI 1083670251 CMS profile 276024

24 Frank Lloyd Wright Dr, Lobby C Suite 1300, Ann Arbor, MI 48105

Open in the dashboard

General payments

$249,825

239 records reported · program years 2019–2025

Research payments

$542,763

Paid to them · 48 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,011,113 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Richard Auchus of Ann Arbor, MI is reported in the CMS Open Payments database as having received $249,825 across 239 general payments and $542,763 in research payments paid to them. Separately, studies naming them as principal investigator received $1,011,113 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

12 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $83,063 73
2025 Research $156,914 6
2024 General $67,706 66
2024 Research $249,815 13
2023 General $37,518 29
2023 Research $133,138 14
2022 General $39,256 39
2022 Research $84 1
2021 General $5,741 9
2021 Research $2,811 14
2020 General $3,225 2
2019 General $13,317 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Richard Auchus
  • Endocrinology, Diabetes & Metabolism median
  • Middle half of Endocrinology, Diabetes & Metabolism
  • National median

In program year 2025, general payments to Richard Auchus were reported at $83,063. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.

Show as a table
Year Richard Auchus Endocrinology, Diabetes & Metabolism median Middle half National median
2019 $13,317 $494 $123–$2,253 $163
2020 $3,225 $335 $85–$1,841 $114
2021 $5,741 $398 $88–$1,981 $132
2022 $39,256 $364 $88–$1,568 $149
2023 $37,518 $420 $113–$1,614 $160
2024 $67,706 $440 $121–$1,646 $164
2025 $83,063 $507 $135–$1,838 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Corcept Therapeutics $93,549 105 payments
  2. Neurocrine Biosciences, Inc. $57,163 78 payments
  3. H. Lundbeck A S $45,277 17 payments
  4. Recordati_Rare_Diseases_Inc. $21,499 16 payments
  5. Xeris Pharmaceuticals, Inc. $14,642 12 payments
  6. Besins Healthcare Ireland Limited $10,163 4 payments
  7. Novo Nordisk Health Care AG $2,520 3 payments
  8. Blue Earth Diagnostics Limited $2,250 1 payment
  9. Roche Diagnostics International Ltd $2,163 1 payment
  10. Novo Nordisk Inc $563 1 payment
  11. Other $37 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $89,492 36 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $61,063 33 payments
  3. Honoraria $47,389 13 payments
  4. Travel and Lodging $45,697 78 payments
  5. Food and Beverage $5,860 78 payments
  6. Education $325 1 payment
Products named General payments · program years 2019–2025
  1. Korlym $89,275 102 payments
  2. CRENESSITY $20,880 18 payments
  3. RECORLEV $12,821 10 payments
  4. OSILODROSTAT $12,165 10 payments
  5. ISTURISA $4,934 4 payments
  6. POSLUMA $2,250 1 payment
  7. Norditropin $563 1 payment
  8. Alkindi $37 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Neurocrine Biosciences, Inc. $288,764 35 payments
  2. Recordati_Rare_Diseases_Inc. $252,643 2 payments
  3. Corcept Therapeutics $1,356 11 payments

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

39

Median for Endocrinology: 1,959

Drug cost

$461,995

Median for Endocrinology: $890,201

Branded share of claims

61.5%

Median for Endocrinology: 57%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Korlym Mifepristone Brand 24 $460,832
Hydrocortisone Generic 15 $1,164

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 6,527 Part D prescribers listed as Endocrinology; they describe a distribution and say nothing about conduct.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Korlym
  • Corcept Therapeutics $24,030
$24,030 24 —
RECORLEV
  • Xeris Pharmaceuticals, Inc. $6,268
$6,268 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

287 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Endocrinology, Diabetes & Metabolism in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record